益安 (6499.TWO)

42.60 -0.20 (-0.47%) 市場開市。 截至 11:40AM CST。

益安

116, HouGang Street
7th Floor
Taipei 11170
Taiwan
886 2 2881 6686
https://www.medeonbio.com

版塊: Healthcare
行業: Medical Instruments & Supplies
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Yue-Teh Jang Ph.D.	Chairman of the Board & CEO	823k	無	無
Dr. Jenny Chen	Spokesperson & CFO	無	無	無
Dr. Yi-Ju Chen	Executive Vice President	無	無	無
Ms. Greta Chang	Executive Vice President	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in Taiwan and the United States. The company focuses on developing devices for minimally invasive surgeries, such as Duett, a vascular graft system; ClickClean, a solution to view throughout laparoscopic surgeries; AbClose to prevent port site herniation caused by improper closure; UroCross, an expander system; PUMA, a solution to treat orthopedic extremity injuries; and Cross-Seal, a large-bore closure device. It is involved in medical device contract manufacturing, equity investment and commerce of medical devices, manufacturing and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is headquartered in Taipei, Taiwan.

公司管治

截至 無 止，益安 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。